C-RAD signs a contract for its GEMini portal imaging detector
March 08 2018 - 2:58AM
C-RAD signs a contract for its GEMini portal imaging detector
C-RAD announced today that it has signed an agreement
with a Chinese company Beijing HGPT Technology & Trade Co., Ltd
regarding the procurement and cooperation around the GEMini Portal
imaging and dosimetry detector.
Following the agreement HGPT has the right to develop a portal
imaging solution for the Chinese market. As part of the agreement
both companies intend to launch a clinical cooperation with Fudan
University Shanghai Cancer Center for the purpose of building up a
local reference site and to support the clinical implementation of
GEMini in China. The objective is to develop a solution can be sold
to hospitals to upgrade their existing linear accelerators with a
portal imaging solution, but also to OEM customers within
China.
GEMini™ is an X-ray detector optimized for so called Portal
Imaging and Portal Dosimetry applications. Whereas Portal Imaging
is providing and solution to position the patient based on the
inner patient anatomy prior to treatment, Portal Dosimetry allows
to monitor the does delivered to the patient during treatment. The
GEMini detector has been developed from the beginning to comply
with these new requirements. The unique design of the GEMini
detector makes it highly radiation-resistant while at the same time
providing optimal dosimetry performance.
The order has a value of approx. 1,5 MSEK and is booked as order
intake in the first quarter. The delivery shall take place during
2018. HGPT is also acting as a distributor for C-RAD’s advanced
patient positioning laser as well as the cutting-edge surface
tracking systems.
Mrs. Wenbing, President HGPT comments:“I am very glad to
cooperate with C-RAD in this new project. HGPT and C-RAD have a
very long cooperation which started with the first product that
C-RAD introduced to the market. I am very excited about this
cooperation to develop a new solution for the Chinese customers, to
bring more value to the Chinese Radiation Therapy field and the
Chinese Patients. This is also another strong message to our
customers, that HGPT is a leading company within advanced Radiation
Therapy Solutions.“
“This project is a good opportunity for C-RAD to present the
performance of the detector.” says Tim Thurn, CEO and President of
C-RAD AB, “While I am excited about this order and the technical
progress we made, I am convinced that the sales of our surface
tracking products will drive the main growth for the company in the
mid-term. The interest in the market for very accurate patient
positioning and monitoring is constantly increasing due to the
broad implementation of high-precision treatment techniques. C-RAD
is in a very good position to serve the customers with a
cutting-edge solution.”
About Beijing HGPT Technology & Trade Co., Ltd.:
HGPT was founded in 1998. Its headquarter office is located in
Beijing and has established offices in Shanghai and Xi’an already.
HGPT is a Professional Supplier for total solutions for the
radiotherapy market, serving a constantly growing customer base
with professional consultation, sales and services.
About C-RAD
C-RAD develops innovative solutions for use in advanced
radiation therapy. The C-RAD group offers products and solutions
for patient positioning, tumor localization and radiation treatment
systems. All product development is conducted in three fully owned
subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD
Innovation AB, all of which are located in Uppsala, Sweden. C-RAD
has established three companies for direct sales: C-RAD Inc. in the
US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa
International SPRL, a Franco-Belgian laser company, is a wholly
owned subsidiary whose operations are integrated. C-RAD AB is
listed on NASDAQ Stockholm. For more information on C-RAD, please
visit http://www.c-rad.com
For further information: Tim Thurn, CEO C-RAD
AB, Phone +46-18-666930, Email investors@c-rad.com
This information is information that C-RAD AB (publ) is obliged
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication at 08:55 CET on March 8,
2018.
PR 20180308 Order GEMini (ENG)
PR 20180308 Order GEMini (ENG)
C-rad Ab (LSE:0R44)
Historical Stock Chart
From Nov 2024 to Dec 2024
C-rad Ab (LSE:0R44)
Historical Stock Chart
From Dec 2023 to Dec 2024